Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1978-10-25
|
pubmed:abstractText |
One hundred-sixty-three children with acute nonlymphocytic leukemia (ANLL) were treated with a multiple-drug induction program (PATCO) consisting of prednisone (PDN), cytosine arabinoside ((Ara-C), 6-thioguanine (6-TG), cyclophosphamide (CPM), and Oncovin (VCR). Ninety-six, 59%, obtained a remission. Remission was maintained with daily 6-TG and four-day pulses of Ara-C and CPM with a single dose of VCR every 28 days. The median duration of remission was 11.5 months. Certain prognostic factors affected induction rate and remission duration. Initial white blood count (WBC) was a significant factor in achieving a remission, whereas age, sex, and type of ANLL had no effect. Initial WBC, age, and sex had a significant effect on remission duration, but type of ANLL had no effect. Relapsing patients were treated with daunomycin and 5-azacytidine. The reinduction rate was 53% with a median second remission duration of 190 days. Overall survival for the 163 patients is 55.4% at 12 months, 31.5% at 24 months, 21.4% at 36 months, and 19% at 48 months.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Thioguanine,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0098-1532
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
4
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
263-73
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:355821-Acute Disease,
pubmed-meshheading:355821-Adolescent,
pubmed-meshheading:355821-Antineoplastic Agents,
pubmed-meshheading:355821-Child,
pubmed-meshheading:355821-Child, Preschool,
pubmed-meshheading:355821-Clinical Trials as Topic,
pubmed-meshheading:355821-Cyclophosphamide,
pubmed-meshheading:355821-Cytarabine,
pubmed-meshheading:355821-Drug Therapy, Combination,
pubmed-meshheading:355821-Female,
pubmed-meshheading:355821-Humans,
pubmed-meshheading:355821-Leukemia,
pubmed-meshheading:355821-Leukocyte Count,
pubmed-meshheading:355821-Male,
pubmed-meshheading:355821-Prednisone,
pubmed-meshheading:355821-Prognosis,
pubmed-meshheading:355821-Remission, Spontaneous,
pubmed-meshheading:355821-Thioguanine,
pubmed-meshheading:355821-Vincristine
|
pubmed:year |
1978
|
pubmed:articleTitle |
Increased survival in childhood acute nonlymphocytic leukemia after treatment with prednisone, cytosine arabinoside, 6-thioguanine, cyclophosphamide, and oncovin (PATCO) combination chemotherapy.
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|